



Contents lists available at [ScienceDirect](http://www.sciencedirect.com)

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Erratum

Erratum to “Imidazopyridines as VLA-4 integrin antagonists” [*Bioorg. Med. Chem. Lett.* 18 (2008) 4146–4149]

David J. Phillips^{a,*}, Richard J. Davenport^{a,†}, Thierry A. Demaude^b, Fiona P. Galleway^a,
Mark W. Jones^a, Laurent Knerr^{b,‡}, Benjamin G. Perry^a, Andrew J. Ratcliffe^a

^aUCB, Granta Park, Great Abington, Cambridge CB21 6GS, UK

^bUCB S.A., R&D, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium

The publisher regrets that some text is missing from the bottom of page 4147 onto the top of page 4148 in the online PDF and the print version of the article. The sentence that begins at the bottom of page 4147 should read:

“We observed an increase in activity when the double bond was substituted as previously described with the gem dimethyl compounds.”

DOI of original article: [10.1016/j.bmcl.2008.05.075](https://doi.org/10.1016/j.bmcl.2008.05.075)

* Corresponding author. Tel.: +44 1223 896535; fax: +44 1223 896400.

E-mail addresses: david.phillips@ucb-group.com, djp1979@yahoo.co.uk (D.J. Phillips).

[†] Present address: Takeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PA, UK.

[‡] Present address: AstraZeneca R&D Mölndal, SE-43183 Mölndal, Sweden.